Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types
Open Access
- 15 April 2014
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 110 (11), 2804-2811
- https://doi.org/10.1038/bjc.2014.198
Abstract
In 2008, a national human papillomavirus (HPV) immunisation programme began in Scotland for 12-13 year old females with a three-year catch-up campaign for those under the age of 18. Since 2008, three-dose uptake of bivalent vaccine in the routine cohort aged 12-13 has exceeded 90% annually, while in the catch-up cohort overall uptake is 66%. To monitor the impact of HPV immunisation, a programme of national surveillance was established (pre and post introduction) which included yearly sampling and HPV genotyping of women attending for cervical screening at age 20. By linking individual vaccination, screening and HPV testing records, we aim to determine the impact of the immunisation programme on circulating type-specific HPV infection particularly for four outcomes: (i) the vaccine types HPV 16 or 18 (ii) types considered to be associated with cross-protection: HPV 31, 33 or 45; (iii) all other high-risk types and (iv) any HPV. From a total of 4679 samples tested, we demonstrate that three doses (n=1100) of bivalent vaccine are associated with a significant reduction in prevalence of HPV 16 and 18 from 29.8% (95% confidence interval 28.3, 31.3%) to 13.6% (95% confidence interval 11.7, 15.8%). The data also suggest cross-protection against HPV 31, 33 and 45. HPV 51 and 56 emerged as the most prevalent (10.5% and 9.6%, respectively) non-vaccine high-risk types in those vaccinated, but at lower rates than HPV 16 (25.9%) in those unvaccinated. This data demonstrate the positive impact of bivalent vaccination on the prevalence of HPV 16, 18, 31, 33 and 45 in the target population and is encouraging for countries which have achieved high-vaccine uptake.Keywords
This publication has 25 references indexed in Scilit:
- Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected ObservationThe Journal of Infectious Diseases, 2013
- Achieving high and equitable coverage of adolescent HPV vaccine in ScotlandJournal of Epidemiology and Community Health, 2013
- Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccineHuman Vaccines & Immunotherapeutics, 2012
- Acceptability and response to a postal survey using self-taken samples for HPV vaccine impact monitoringSexually Transmitted Infections, 2011
- Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological studyThe Lancet, 2011
- HPV type-specific prevalence using a urine assay in unvaccinated male and female 11- to 18-year olds in ScotlandBritish Journal of Cancer, 2011
- Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide studyThe Lancet Oncology, 2010
- Distribution of HPV types associated with cervical cancers in Scotland and implications for the impact of HPV vaccinesBritish Journal of Cancer, 2010
- Bead-Based Multiplex Genotyping of Human PapillomavirusesJournal of Clinical Microbiology, 2006
- The global health burden of infection‐associated cancers in the year 2002International Journal of Cancer, 2006